secretome

Phase 1Cell therapy

BBaermed

secretome is one of 141 biologic programs targeting Cognitive impairment. It is currently in Phase 1.

Indications

Total Trials

Active Trials

140

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Androgenetic AlopeciaActive, not recruiting

EpilepsyActive, not recruiting

CirrhosisActive, not recruiting

Cognitive ImpairmentPhase 1

Active, not recruiting

Androgenetic AlopeciaPhase 1/Phase 2

Active, not recruiting

EpilepsyPhase 1

Active, not recruiting

CirrhosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

279 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Actos

Takeda

Phase 3

3 2

Farxiga

AstraZeneca

Phase 3

1 3

Provigil

NNuvo Research GmbH

Phase 3

1 4

Xarelto

WWim Janssens

Phase 3

1 5

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 6

Viagra

VViatris Specialty LLC

Phase 3

1 7

Donepezil Hydrochloride

Eisai

Phase 3

3 8

Statins

Sanofi

Phase 3

1 9

Galantamine Hydrobromide

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

4 10

Karx-EC

Bristol-Myers Squibb

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Recruiting

Androgenetic Alopecia

NCT07429253

Q4 2026

Phase 1Not yet recruiting

Epilepsy

NCT06638970

Phase 1Not yet recruiting

Cirrhosis

NCT06629909

Clinical

Trials by Indication[1]

Stem Cell1 trial

Skin Rejuvenation Using Stem Cell Secretome

Completed·CCOR clinic of Regenerative Medicine·Phase 1·NCT06217627·49 enrolled

Acne Vulgaris1 trial

The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne Treatment

Not yet recruiting·UUniversitas Padjadjaran·Phase 2·NCT06925386·64 enrolled

Epilepsy1 trial

Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Drug Resistant Epilepsy Single Center, Non-randomized, Phase I Clinical Trial

Not yet recruiting·BBaermed·Phase 1·NCT06638970·54 enrolled

Mesenchymal Stem Cell1 trial

The Effects of Mesenchymal Stem Cell Secretome in Lupus Patients

Completed·UUniversitas Sebelas Maret·Phase 1/2·NCT05921058·15 enrolled

Androgenetic Alopecia1 trial

Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients

Recruiting·PPT. Prodia Stem Cell Indonesia·Phase 1/2·NCT07429253·40 enrolled

3 more indications

Cognitive impairment1 trial

Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Moderate Neurocognitive Impairment (Dementia)

Not yet recruiting·BBaermed·Phase 1·NCT06632470·54 enrolled

Cirrhosis1 trial

Safety and Feasibility of Human Umbilical Cord Mesenchymal Stem Cell-Derived Secretome in the Treatment of Liver Cirrhosis: a Comprehensive Evaluation of Fibrosis Reduction, Immunomodulation, and Hepatic Regeneration: a Single Center, Randomized, Phase I Clinical Trial

Not yet recruiting·BBaermed·Phase 1·NCT06629909·54 enrolled

TIA1 trial

Potential Injection of Human Umbilical Cord Secretome in the Case of Trophic Ulcers (Pre-post Intervention)

Completed·YYohanes Firmansyah, dr, MH, MM·Phase 1·NCT05777213·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for secretome. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — secretome compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for secretome. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Baermed company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: BBaermed

secretome

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Stem Cell1 trial

Acne Vulgaris1 trial

Epilepsy1 trial

Mesenchymal Stem Cell1 trial

Androgenetic Alopecia1 trial

Cognitive impairment1 trial

Cirrhosis1 trial

TIA1 trial

References

Drug Info

Quick Facts

Related News